CLYM
Climb Bio, Inc.
Key Financials
Net Income
$-59851000
↑ 19.0%
Operating Income
$-67883000
↑ 17.2%
EPS (Diluted)
$-0.88
↑ 42.5%
Shareholders' Equity
$160.5M
↓ 24.3%
Total Liabilities
$7.3M
↑ 37.0%
Total Assets
$167.7M
↓ 22.8%
Cash & Equivalents
$35.7M
↓ 59.1%
Operating Cash Flow
$-54356000.00
↓ 249.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 9/30/2026 | View on SEC |
| 4 | 9/17/2026 | View on SEC |
| 144 | 9/15/2026 | View on SEC |
| 8-K | 9/3/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 8-K | 8/14/2026 | View on SEC |
| 10-Q | 8/6/2026 | View on SEC |
| 8-K | 8/6/2026 | View on SEC |
| SCHEDULE 13G | 7/8/2026 | View on SEC |
| SCHEDULE 13D/A | 7/7/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CLYM |
| Company Name | Climb Bio, Inc. |
| CIK | 1768446 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 1-866-857-2596 |